상세 보기
Risk factors for the failure of first-line PARP inhibitor maintenance therapy in patients with advanced ovarian cancer: Gynecologic Oncology Research Investigators Collaboration Study (GORILLA-3004)
- Kim, Nam Kyeong;
- Kim, Yeorae;
- Kim, Hee Seung;
- Park, Soo Jin;
- Hwang, Dong Won;
- ... Lee, Yoo-Young;
- 외 9명
WEB OF SCIENCE
8SCOPUS
6초록
ObjectiveTo identify the risk factors for failure of first-line poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy in patients with advanced ovarian cancer.MethodPatients with stage III-IV epithelial ovarian cancer who received first-line PARPi maintenance therapy were retrospectively reviewed. Clinicopathologic factors were compared between two groups-recur/progression of disease (PD) and non-recur/PD.ResultsIn total, 191 patients were included. Median follow-up was 9.9 months, and recurrence rate was 20.9%. BRCA mutations were found in 63.4% patients. Postoperative residual tumor (60.5% vs. 37.8%), non-high grade serous carcinoma (HGSC) (15.0% vs. 6.0%), neoadjuvant chemotherapy (NAC) (55.0% vs. 35.8%), and pre-PARPi serum CA-125 levels >= 23.5 U/mL (35.9% vs. 15.2%) were more frequently observed in the recur/PD group. Multivariate Cox-regression analysis revealed pre-PARPi serum CA-125 levels >= 23.5 U/mL (HR, 2.17; 95%CI, 1.03-4.57; p = 0.042), non-HGSC (3.28; 1.20-8.97; p = 0.021), NAC (2.11; 1.04-4.26; p = 0.037), and no BRCA mutation (2.23; 1.12-4.44; p = 0.023) as independent risk factors associated with poor progression-free survival (PFS). A subgroup analysis according to BRCA mutation status showed that pre-PARPi serum CA-125 levels >= 26.4 U/mL were the only independent risk factor for poor PFS in women with BRCA mutations (2.75; 1.03-7.39; p = 0.044). Non-HGSC (5.05; 1.80-14.18; p = 0.002) and NAC (3.36; 1.25-9.04; p = 0.016) were independent risk factors in women without BRCA mutations.ConclusionHigh pre-PARPi serum CA-125 levels, non-HGSC histology, NAC, and no BRCA mutation might be risk factors for early failure of first-line PARPi maintenance therapy. In women with BRCA mutations, high pre-PARPi serum CA-125 levels, which represent a large tumor burden before PARPi, were the only independent risk factor for poor PFS.
키워드
- 제목
- Risk factors for the failure of first-line PARP inhibitor maintenance therapy in patients with advanced ovarian cancer: Gynecologic Oncology Research Investigators Collaboration Study (GORILLA-3004)
- 저자
- Kim, Nam Kyeong; Kim, Yeorae; Kim, Hee Seung; Park, Soo Jin; Hwang, Dong Won; Lee, Sung Jong; Yoo, Ji Geun; Chang, Suk-Joon; Son, Joo-Hyuk; Kong, Tae-Wook; Kim, Jeeyeon; Shim, Seung-Hyuk; Lee, A. Jin; Suh, Dong Hoon; Lee, Yoo-Young
- 발행일
- 2023-10
- 유형
- Article
- 저널명
- Cancer Medicine
- 권
- 12
- 호
- 19
- 페이지
- 19449 ~ 19459
- 언어
- ENG
- 출판사
- John Wiley and Sons Ltd
- 발행국가
- 미국
- 분량
- 11 페이지
- ISSN
- E 2045-7634